Find information on thousands of medical conditions and prescription drugs.

Carbimazole

Carbimazole is used to treat hyperthyroidism. It prevents the peroxidase enzyme from coupling and iodinating the tyrosine residues on thyroglobulin, hence reducing the T3/T4.

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Acute myocardial infarction in a young male patient with combined hormonal disorder - Letter to the Editor
From CHEST, 12/1/02

To the Editor:

Lehmann and colleagues reported in CHEST (July 2000) (1) a case of a young female patient with primary hypoparathyroidism and a clinical presentation mimicking acute myocardial infarction. In addition, RuDusky, in an article in CHEST (February 2001), (2) also referred to ECG abnormalities that are associated with hypocalcemia. The significance of serum calcium levels for normal myocardial and vascular function has been established, even if cardiovascular complications are not typical in hypoparathyroidism. A combination of parathyroid and thyroid gland dysfunction is usual in the postoperative period because of their anatomic proximity. Obviously, a combination of thyroid and parathyroid gland disorders could provoke complex cardiovascular complications.

We would like to present here our experience with a 37-year-old male patient who was admitted to our department because of chest pain. Laboratory findings and ST-segment elevation on his ECG were indicative of acute myocardial infarction. He had no coronary artery disease history, he did not use drugs or alcohol, and, except for a history of moderate smoking, he had no other risk factors for coronary artery disease. A history of subtotal thyroidectomy 17 years before hospital admission was reported. Since then, he had not undergone any medical follow-up, as he had been totally asymptomatic. A suspicion of a metabolic disorder was confirmed because of QT-interval prolongation on the ECG and a clinical examination finding that was positive for Trousseau sign. Laboratory analysis revealed severe hypocalcemia ([Ca.sup.2+] level, 5.86 mg/dL; normal range, 8.2 to 10.7 mg/dL), hyperphosphatemia (phosphate level, 6.06 mg/dL; normal range, 2.4 to 4.9 mg/dL), and low serum levels of parathyroid hormone (parathyroid hormone level, 5 pg/mL; normal range, 10 to 55 pg/mL), while thyroid-function tests revealed hyperthyroidism (human thyroid-stimulating hormone level, 0.005 IU/mL; normal range, 0.27 to 4.2 IU/mL; and free 3,5,3'-triiodothyronine level, 7 pg/mL; normal range, 1.82 to 4.62 pg/mL).

After thrombolysis and the proper treatment of patients with acute myocardial infarction in the ICU, supplementation of therapy with calcium and vitamin [D.sup.3], as well as antithyroid drugs (ie, carbimazole, 15 mg three times per day) was initiated. Cardiac catheterization showed one-vessel disease (ie, 70% stenosis of the proximal section of the left anterior descending coronary artery), which was treated with angioplasty and stenting. Thereafter, the patient remained asymptomatic, living a normal life, and is receiving antiangina therapy (ie, [beta]-blockers, angiotensin-converting enzyme inhibitors, and aspirin), calcium and vitamin [D.sub.3] supplementation, and antithyroid drugs.

There are only few case reports (1,3) in the literature of severe hypocalcemia mimicking acute myocardial infarction. The most likely mechanism, suggested by Lehmann and colleagues, (1) is coronary vasospasm, as the patient appeared to have normal coronary arteries, while in the second case, the patient was proved to have reversible cardiomyopathy induced by hypocalcemia. Coronary vasospasm and increased oxygen demands also have been described as mechanisms of myocardial infarction in patients with hyperthyroidism and normal coronary arteries. (4,5)

Evidently, our patient presented with two different risk factors for coronary circulation aggravation that could induce acute coronary syndrome, even in a normal vascular bed. The incidence of premature atherosclerosis in this case cannot be attributed to the combined hormonal disorder, as there is no such evidence for it in the literature.

In conclusion, the unusual clinical course of our patient, in combination with the rarity of acute myocardial infarction in patients with combined "hidden" postoperative hypoparathyroidism and hyperthyroidism, long after undergoing subtotal thyroidectomy, makes our case interesting.

Correspondence to: Eleftheriadis Damianos, MD, Cardiologist, "Mpodosakio" Hospital of Ptolemaida, North Greece, Politechniu 3 Triandria, 55337 Thessaloniki, Greece; e-mail: pipinely@yahoo.com

REFERENCES

(1) Lehmann G, Deisenhofer I, Ndrepepa G, et al. ECG changes in a 25-year-old woman with hypocalcemia due to hypoparathyroidism. Chest 2000; 118:260-262

(2) RuDusky BM. ECG abnormalities associated with hypocalcemia. Chest 2001; 119:668-669

(3) Rallidis LS, Gregoropoulos PP, Papasteriadis EG. A case of severe hypocalcemia mimicking myocardial infarction. Int J Cardiol 1997; 61:89-91

(4) Masani ND, Northridge DB, Hall RJ. Severe coronary vasospasm associated with hyperthyroidism causing myocardial infarction. Br Heart J 1995; 74:700-701

(5) Locker GJ, Kotzmann H, Frey B, et al. Factitious hyperthyroidism causing acute myocardial infarction. Thyroid 1995; 5:465-467

To the Editor:

With respect to the data that form the framework, I do not think that they add essentially to the current knowledge of hypoparathyroidism and subsequent hypocalcaemia with the potential of mimicking acute myocardial infarction (AMI). There is the situation of a young patient with chest pain and ill-defined laboratory findings as well as ECG changes (including QT-interval prolongation) indicative of AMI which, after laboratory analyses of both endocrinologic parameters and coronary angiography have been performed, is found to be hypocalcemia-induced reversible cardiomyopathy, as occurred in our case. Accordingly, from an objective point of view, I do not deem this contribution worth answering so far.

Nevertheless, there are some aspects that deserve mention. The report by Damianos lacks a description of ECG changes, as it does with respect to initial laboratory findings. In contrast, our report specified changes rendering the situation suspicious of AMI.

Furthermore, hypoparathyroidism is presented in the same breath as hyperthyroidism, which, in turn, according to current knowledge, would lead to a mild elevation of serum calcium. There is an objective basis for hypoparathyroidism because of a subtotal thyroidectomy some 17 years earlier. But what about the hyperthyroidism? Couldn't that be a completely different clinical entity--brought about, for example, by some autonomic nodules having accrued over the years? And couldn't this situation lead to tachycardia which, in turn, together with the proximal 70% stenosis of the left anterior descending coronary artery (LAD), would be apt to produce ECG changes suspicious of myocardial ischaemia? Neither are data given in their report concerning the heart rate in their ECG on hospital admission, nor on ST-segments, etc.

In addition, thrombolysis and subsequent angioplasty were performed. No comment was made with respect to a putative contribution of an occlusion of the LAD on hospital admission. And I also miss a description of the left ventricular ejection fraction, which is known to be impaired globally upon some metabolic disorders as, eg, hypocalcemia, but rather regionally upon vessel occlusion.

Finally, a remark is added teaching us that two different factors are to be assumed with the potential of inducing an acute coronary syndrome, but without specifying them, and the presentation ends with a reference to premature atherosclerosis. This, in turn, was unambiguously discussed two paragraphs earlier, where the discussion centered around the issue of whether or not the 70% stenosis of the LAD (after thrombolysis) could have contributed to the clinical setting of hypocalcemia-induced AMI mimickry.

Correspondence to: Gunter Lehmann, MD, Resident Cardiologist, Deutsches Herzzentrum Munchen, Lazarettestrasse 36, D-80636 Munich, Germany

COPYRIGHT 2002 American College of Chest Physicians
COPYRIGHT 2003 Gale Group

Return to Carbimazole
Home Contact Resources Exchange Links ebay